Clinical Trial Update: Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating isatuximab for adults with relapsed/refractory CD38-positive T-cell acute lymphoblastic leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• SARCLISA (isatuximab)

Snippet

Sponsor: Goethe University | Conditions: T-ALL | Phase 2 | Status: RECRUITING